Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics natural incretin hormones to regulate blood glucose and promote weight loss. Available as FDA-approved Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as the first oral GLP-1 medication. Clinical trials demonstrate exceptional efficacy with 14.9% average weight loss and 26% reduction in major cardiovascular events.

Complete Research Database

0
Major Studies
0
Total Participants
5
Research Articles
N/A
Years of Research

Safety Analysis

Adverse event data from clinical trials

Generally Well-Tolerated

Adverse Event Frequencies

Low (<10%)
Moderate (10-25%)
High (>25%)
44.2%
High
nausea
30.1%
High
diarrhea
24.8%
Moderate
vomiting
23.4%
Moderate
constipation
20.3%
Moderate
abdominal pain
18.6%
Moderate
decreased appetite
6.8%
Low
injection site reactions

Clinical Safety Notes

Timing
GI side effects typically occur during dose escalation
Severity
Most adverse events are mild to moderate in severity
Adherence
Discontinuation rate due to side effects: ~5.3%
Safety
No increased risk of pancreatitis in clinical trials
Monitoring
Regular monitoring recommended for thyroid function

Medical Disclaimer

Semaglutide is FDA-approved as Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as oral GLP-1 therapy. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.